Journal List > J Korean Assoc Pediatr Surg > v.21(2) > 1071956

Chun, Kim, Kim, and Namgoong: Postoperative Monotherapy with Piperacillin-Tazobactam versus Multidrug Therapy with Cefotaxime and Metronidazole for Perforated Appendicitis in Children: A Case-Control Study

Abstract

Purpose

Recent data suggest that monotherapy with a broad-spectrum antibiotic may be as efficacious as, and potentially less costly than, standard multi-drug therapy. We compared mono-therapy with intravenous piperacillin-tazobactam (PT) with multi-drug therapy with cefotaxime and metronidazole (CM) in aspect of postoperative complications and hospital stay.

Methods

We reviewed the hospital records and medical costs of the pediatric patients who were managed for perforated appendicitis between April 2013 and May 2014 retrospectively.

Results

Forty-six patients with laparoscopic appendectomy for perforated appendicitis were included in our study. PT group was 20 and CM group was 26 patients. On admission, there were no significance in sex distribution, duration of symptoms, leukocyte count, and CRP levels. At postoperative third, fifth, and seventh day of each regimen, PT group have no statistical difference with CM group in leukocyte count, percentage of neutrophil, and CRP. There was no difference in abscess formation rate, wound infections, and hospital stay between two groups. There was only one patient who was readmitted with elevation of CRP and leukocyte count in CM group.

Conclusion

Daily dosing with the mono-therapy of PT offers as efficient as multi-drug therapy of CM. To evaluate the efficacy of broad-spectrum antibiotics monotherapy in perforated appendicitis children, the cohort included more patients should be needed.

Figures and Tables

Table 1
Perioperative Patients Characteristics and Laboratory Findings
jkaps-21-28-i001

Values are presented as ratio, mean±SD, or n (%).

PT, piperacillin-tazobactam; CM, cefotaxime and metronidazole.

Table 2
Perioperative and Postoperative Findings
jkaps-21-28-i002

Values are presented as mean±SD, ratio, or n (%).

PT, piperacillin-tazobactam; CM, cefotaxime and metronidazole.

Table 3
Inflammatory Index according to the Postoperative Day (POD)
jkaps-21-28-i003

Values are presented as mean±SD or n (%).

PT, piperacillin-tazobactam; CM, cefotaxime and metronidazole.

Table 4
FFS vs. DRG
jkaps-21-28-i004

Values are presented as mean±SD.

FFS, fee for service; DRG, diagnosis related group; PT, piperacillin-tazobactam; CM, cefotaxime and metronidazole; KRW, Korean Won.

Notes

CONFLICTS OF INTEREST No potential conflict of interest relevant to this article was reported.

The abstract of this article was presented at the 66th Annual Congress of the Korean Surgical Society, November 28, 2014.

References

1. Williams RF, Interiano RB, Paton E, Eubanks JW, Huang EY, Langham MR, et al. Impact of a randomized clinical trial on children with perforated appendicitis. Surgery. 2014; 156:462–466.
2. Zerem E, Imamović G, Ljuca F, Alidžanović J. What is the optimal treatment for appendiceal mass formed after acute perforated appendicitis. World J Gastroenterol. 2012; 18:1849–1850.
3. Bauer T, Vennits B, Holm B, Hahn-Pedersen J, Lysen D, Galatius H, et al. Antibiotic prophylaxis in acute nonperforated appendicitis. Ann Surg. 1989; 209:307–311.
4. Pieper R, Kager L, Näsman P. Acute appendicitis: a clinical study of 1018 cases of emergency appendectomy. Acta Chir Scand. 1982; 148:51–62.
5. Browder W, Smith JW, Vivoda LM, Nichols RL. Nonperforative appendicitis: a continuing surgical dilemma. J Infect Dis. 1989; 159:1088–1094.
6. Bates T, Touquet VL, Tutton MK, Mahmoud SE, Reuther JW. Prophylactic metronidazole in appendicectomy: a controlled trial. Br J Surg. 1980; 67:547–550.
7. Hopkins JA, Lee JC, Wilson SE. Susceptibility of intra-abdominal isolates at operation: a predictor of postoperative infection. Am Surg. 1993; 59:791–796.
8. Curran TJ, Muenchow SK. The treatment of complicated appendicitis in children using peritoneal drainage: results from a public hospital. J Pediatr Surg. 1993; 28:204–208.
9. Gollin G, Abarbanell A, Moores D. Oral antibiotics in the management of perforated appendicitis in children. Am Surg. 2002; 68:1072–1074.
10. Lund DP, Murphy EU. Management of perforated appendicitis in children: a decade of aggressive treatment. J Pediatr Surg. 1994; 29:1130–1134.
11. Fishman SJ, Pelosi L, Klavon SL, O'Rourke EJ. Perforated appendicitis: prospective outcome analysis for 150 children. J Pediatr Surg. 2000; 35:923–926.
12. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004; 240:205–213.
13. Newman K, Ponsky T, Kittle K, Dyk L, Throop C, Gieseker K, et al. Appendicitis 2000: variability in practice, outcomes, and resource utilization at thirty pediatric hospitals. J Pediatr Surg. 2003; 38:372–379.
14. Chen C, Botelho C, Cooper A, Hibberd P, Parsons SK. Current practice patterns in the treatment of perforated appendicitis in children. J Am Coll Surg. 2003; 196:212–221.
15. Rice HE, Brown RL, Gollin G, Caty MG, Gilbert J, Skinner MA, et al. Results of a pilot trial comparing prolonged intravenous antibiotics with sequential intravenous/oral antibiotics for children with perforated appendicitis. Arch Surg. 2001; 136:1391–1395.
16. Nadler EP, Reblock KK, Ford HR, Gaines BA. Monotherapy versus multi-drug therapy for the treatment of perforated appendicitis in children. Surg Infect (Larchmt). 2003; 4:327–333.
TOOLS
Similar articles